Risultati per: La FDA approva il sistema di riabilitazione dell’ictus

Dense breasts place people at higher risk of breast cancer but also make it harder to pick up abnormalities on x-rays. A new rule by the US Food and Drug Administration (FDA) standardizes the information patients receive from their mammogram providers about their breast density. It also requires language prompting patients—particularly those with dense breasts—to talk in greater depth with their physicians about their results and whether additional imaging makes sense.

The US Food and Drug Administration (FDA) recently approved trofinetide, an oral solution marketed as Daybue, for the treatment of Rett syndrome, a rare genetic disorder that alters brain development, among adults and children aged 2 years or older. Common adverse effects of the twice-daily oral drug include diarrhea and vomiting, an FDA statement noted.

Terapia CAR-T a Bambino Gesù, 36% senza tracce malattia a 3 anni

Ministro vede presidente Balzanelli, primo passo per nuovo Ssn

New England Journal of Medicine, Ahead of Print.

This cross-sectional study determines the frequency of and rationale for US Food and Drug Administration (FDA) approval of drugs not meeting pivotal trial primary efficacy end points.

This cross-sectional study evaluates regulatory decisions and health technology assessments in Australia, Canada, and the UK regarding new drugs approved by the US Food and Drug Administration in 2017 through 2020, as well as estimates the US cost per patient per year for drugs receiving negative recommendations.

This cross-sectional study evaluates patient exposure to oncology drugs withdrawn from the US Food and Drug Administration (FDA) Accelerated Approval program.

Soc. italiana ictus, ‘urge omogeneità cura su tutto territorio’

Con la campagna didattica Fast Heroes di Alice Italia

In late February, the US Food and Drug Administration (FDA) granted an Emergency Use Authorization to an at-home diagnostic test that identifies SARS-CoV-2, the virus that causes COVID-19, as well as influenza strains A and B. The test detected 100% of negative and 88.3% of positive COVID-19 samples, 99.3% of negative and 90% of positive influenza A samples, and 99.9% of negative influenza B samples.

La campagna mondiale dal 13 al 19 marzo

New England Journal of Medicine, Ahead of Print.

Per gli adulti, agisce in 15 minuti su dolore e altri sintomi